These two businesses could receive a big boost this month if certain events fall in their favor.
News & Analysis: Novo Nordisk
The second quarter wasn't too shabby either.
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
Oral semaglutide is on its way.
NVO earnings call for the period ending March 31, 2019.
The full year may be a different story.
NVO earnings call for the period ending December 31, 2018.
Diabetes and related conditions affect over 100 million Americans and many more worldwide. Here are three companies helping fight that disease.
Experimental new drugs at critical stages of development could soon send these stocks screaming in one direction or another.
Growth on one hand, but declines on the other.